Supplements
Download PDF
Gary M. Owens, MD

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: September 15th, 2009 - September 15th, 2010

This activity is no longer available for credit, however its content is still relevant for your educational needs.

Target Audience
This activity was developed for pharmacy directors, P&T Committee members, managed care pharmacists, oncology pharmacists, and other key stakeholders who wish to enhance their knowledge concerning the implementation of a value-based benefit design for cancer care.

Learning Objectives
At the completion of this activity participants should be able to:

  • Provide payers with a practical understanding of the key clinical, business, and regulatory factors, guidelines, and research advances involving breast cancer treatment that providers are using as the basis for their treatment decisions
  • Offer payers a multistakeholder commentary on this information, to identify the impact on different stakeholders of these changes to treatment
  • Illuminate the different perspectives and incentives of the various stakeholders involved in breast cancer treatment decisions: patients, providers, payers, purchasers, distributors, regulatory agencies, and manufacturers
  • Align incentives with providers and transform payer drug management policies into patient-centered, value based models


Disclosure Statement
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker’s bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

The associates of Medical Learning Institute, Inc., and Center of Excellence Media, LLC, have no financial relationships to disclose.

Dr Owens is a consultant to AstraZeneca, Genentech, and Wyeth, and is on the advisory board of ImClone Systems, Roche, and sanofi-aventis.

Faculty Disclosures
Gary M. Owens, MD, is a Consultant to Asthmatx, Biosense Webster, Centocor-OrthoBiotech, Eli Lilly, Genentech, and Novartis.


*Content will include non-FDA-approved uses.

Disclaimer
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Related Items
New Directions in the Treatment and Symptom Management of Multiple Sclerosis – Part 2
Samuel F. Hunter, MD, PhD, Gary M. Owens, MD
Interactive Learning published on June 13, 2013
Myelofibrosis and Multiple Myeloma: Strategies for Effective Decision-Making
Martha L. Arellano, MD, Jonathan L. Kaufman, MD , James T. Kenney Jr, RPh, MBA, Gary M. Owens, MD
Supplements published on July 31, 2012
Emerging Treatments and Evolving Strategies for the Cost-Effective Management of Myelofibrosis
Gary M. Owens, MD, Alfonso Quintas-Cardama, MD , Atheer A. Kaddis, PharmD
Interactive Learning published on July 15, 2012
Optimizing New and Emerging Therapies for Treatment and Symptom Management of Multiple Sclerosis in Managed Care
Gary M. Owens, MD, Bruce L. Hughes, MD , Sonya J. Lewis, RPh, MBA
Supplements published on August 2, 2011
Wellness and Prevention in Chronic Disease Consensus Statement
Gary M. Owens, MD, Nirav R. Shah, MD, MPH, FACP, Michael McLean, RPh, MPA, Kip Piper, MA, FACHE, Doug Burgoyne, PharmD, John Fox, MD, Stacie Heller, Wayne M. Lednar, MD, PhD, Lynne Rothney-Kozlak, Scott R. Taylor, RPh, MBA, F. Randy Vogenberg, RPh, PhD
Supplements published on September 30, 2010
Highlights from ASCO 2010: An Update for Payers and Providers on Chronic Myelogenous Leukemia
Gary M. Owens, MD, Michael Mauro, MD
Supplements published on September 15, 2010
Health System/Regional Variations in the Delivery of Care for Multiple Myeloma
Gary M. Owens, MD, Jatin Shah, MD, Rusty Crawford, RPh, BCOP, Sin (Masha) Lam, PharmD, BCOP, Stephanie S. Minich, PharmD, BCOP
Supplements published on March 30, 2010
Value-Based Oncology Benefit Design™ Balancing Cost, Quality, and Access in Cancer Care
Gary M. Owens, MD, Al B. Benson III, MD, FACP, Gary Rice, RPh, MS, MBA
Supplements published on June 30, 2009
Value-Based Oncology Benefit Design: Cost, Quality, and Access Considerations in Colorectal Cancer Care
Gary M. Owens, MD, John Fox, MD
Supplements published on April 30, 2009
Value-Based Oncology Benefit Design: Breast Cancer, Multiple Myeloma, and Prostate Cancer
Kavita V. Nair, PhD, Gary M. Owens, MD, Al B. Benson III, MD, FACP
Supplements published on February 20, 2009
Last modified: March 24, 2014